longbridge

William Blair downgrades Cardiff Oncology (CRDF) to a Hold

Tip Ranks
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Cardiff Oncology received a Hold rating and price target from William Blair analyst Andy Hsieh today.

Claim 55% Off TipRanks

  • Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
  • Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Hsieh covers the Healthcare sector, focusing on stocks such as Cardiff Oncology, Lantheus, and Viking Therapeutics. According to TipRanks, Hsieh has an average return of 9.8% and a 48.52% success rate on recommended stocks.

Cardiff Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy